OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Treatment Reviews is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Editorial Board	236
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer	224
Current indications and future perspectives for antibody-drug conjugates in brain metastases of breast cancer	221
Adjuvant CDK4/6 inhibitors in breast cancer: Interpreting trial design, evidence, and uncertainty	162
The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint in	139
Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review	138
Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives	130
Late hepatic toxicity surveillance for survivors of childhood, adolescent and young adult cancer: Recommendations from the international late effects of childhood cancer guideline harmonization group	117
Systemic therapy for older patients with early breast cancer	107
Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis	97
The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas	90
The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer	84
A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC)	80
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials	79
FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma	78
Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications	78
Editorial Board	72
De-escalation strategies with targeted therapies in non-small cell lung cancer	72
Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches	71
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev.	68
If it’s a target, it’s a pan-cancer target: Tissue is not the issue	64
Emerging antibody-based therapies for the treatment of acute myeloid leukemia	64
Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis	63
First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features	63
Tailoring adjuvant endocrine therapy in early breast cancer: When, how, and how long?	62

Surgical tumor volume reduction in patients with brain metastases: A systematic review and meta-analysis	61
Optimizing care in early phase cancer trials: The role of palliative care	60
Opportunities and challenges for non–small cell lung cancer brain metastases in the immunotherapy era	58
Emerging mechanisms of triple-negative breast cancer radioresistance: Interplay between cancer cell mechanisms and the tumor immune microenvironment	56
Editorial Board	55
Uncertainties and controversies in axillary management of patients with breast cancer	52
Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck	52
Optimizing diagnosis and treatment of EGFR exon 20 insertions mutant NSCLC	52
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?	51
Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations	49
Risk of thromboembolic events in patients with metastatic solid tumors treated with PARP inhibitors: A systematic review and meta-analysis of phase 3 randomized controlled trials	48
Havoc in harmony: Unravelling the intricacies of angiogenesis orchestrated by the tumor microenvironment	46
Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes	46
Roadmap to cure multiple myeloma	46
Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy	45
Editorial Board	44
Overview of BH3 mimetics in ovarian cancer	43
Extracellular vesicles and the “six Rs” in radiotherapy	43